A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Pamrevlumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms ZEPHYRUS
- Sponsors FibroGen
- 22 Jul 2019 According to a FibroGen media release, first patient has been dosed in the trial. Subjects who complete the 52-week study may be eligible for rollover into a separate study offering open-label, extension treatment with pamrevlumab.
- 09 Jul 2019 Status changed from not yet recruiting to recruiting.
- 16 May 2019 Status changed from planning to not yet recruiting.